Evidence map›Paper›PMID 40820933›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2025

Treg-specific IL-6R signaling: a novel role in the regulation of the intestinal epithelium.

Emily E Klatt, Feda H Hamdan, Isaiah Pérez, Hannah M Smith, Kimberlee Kossick, Yaroslav Fedyshyn, Mary R Sagstetter, David Chiang, Lucas C S Chini, Heidi M Davidson and 7 more

Abstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Emily E KlattDepartment of Immunology, Mayo Clinic, Rochester, Minnesota, United States.
Feda H HamdanDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, United States.
Isaiah PérezDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Hannah M SmithDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0001-9487-2560
Kimberlee KossickDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0001-8120-7617
Yaroslav FedyshynDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Mary R SagstetterDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
David ChiangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Lucas C S ChiniDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, United States.
Heidi M DavidsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Maria S WestphalDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Naomi M GadesDepartment of Comparative Medicine, Mayo Clinic, Scottsdale, Arizona, United States.
Rohini MopuriDivision of Computational Biology, Mayo Clinic, Rochester, Minnesota, United States.
Zhifu SunDivision of Computational Biology, Mayo Clinic, Rochester, Minnesota, United States.
Wale O BamideleDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0002-9547-2195
Brooke R DrulinerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0000-0001-9254-8097
William A FaubionDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, United States.

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
MULTIDISCRIPLINARY TRAINING IN DIGESTIVE DISEASEST32DK007198 · NIDDK · MAYO CLINIC ROCHESTER · PI Harmeet Malhi · 1986 to 2026
$8.9M
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.R01AI089714 · NIAID · MAYO CLINIC ROCHESTER · PI FAUBION, WILLIAM A · 2011 to 2025
$6.3M
Gastrointestinal Cues Influence Metabolic Control of Regulatory T cell FunctionK01DK124358 · NIDDK · MAYO CLINIC ROCHESTER · PI BAMIDELE, ADEBOWALE O · 2020 to 2024
$723k
AGA Research Foundation (American Gastroenterological Association AGA) Research Scholar AwardHHS | National Institutes of Health (NIH) R01AI089 714-022HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK084567HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) T32DK007198NIAID NIH HHS R01 AI089714NIDDK NIH HHS K01 DK124358NIDDK NIH HHS P30 DK084567NIDDK NIH HHS T32 DK007198
6 · The paper itself

Abstract

Mucosal homeostasis requires coordinated immune regulation and epithelial repair. Inflammatory bowel disease (IBD) arises from disrupted coordination between the immune system and intestinal epithelium, where resolution and repair must occur in parallel. Interleukin-6 (IL-6) plays a dual role: it promotes epithelial regeneration but destabilizes regulatory T cells (Tregs). We aimed to determine the contribution of Treg IL-6 receptor (IL-6R) signaling to intestinal inflammation and epithelial integrity. We developed a conditional knockout mouse model in which IL-6R was deleted from Tregs (Treg IL-6R knockout). These mice were subjected to dextran sodium sulfate (DSS)-induced colitis and a T cell transfer model of colitis. Soluble IL-6R production by Tregs was assessed in vitro, and transcriptional changes in epithelial cells were analyzed by RNA-seq. Human colonic organoids from patients with IBD were treated with IL-6 or hyper-IL-6 (IL-6/sIL-6R fusion protein) to test downstream signaling effects. Tregs lacking IL-6R improved colitis to a similar extent as control Tregs in the adoptive transfer model, indicating intact suppressive function. However, Treg IL-6R knockout mice were more susceptible to DSS colitis than controls, suggesting a physiologic role for Treg IL-6R signaling in epithelial protection. In vitro, Tregs shed soluble IL-6R, enabling IL-6 trans-signaling to epithelial cells. Intestinal epithelial cells from Treg IL-6R knockout mice compared with WTcre controls revealed widespread transcriptional downregulation of genes related to survival and repair pathways at baseline, and impaired transcriptional responses following DSS treatment. In human organoids, IL-6 trans-signaling elicited stronger STAT3 activation than IL-6 alone. These findings reveal a previously unrecognized role for Treg-derived IL-6R in promoting epithelial resilience and maintaining mucosal homeostasis.

Indexed as

ColitisIntestinal MucosaReceptors, Interleukin-6T-Lymphocytes, RegulatoryAnimalsDextran SulfateDisease Models, AnimalHumansInflammatory Bowel DiseasesInterleukin-6MiceMice, Inbred C57BLMice, KnockoutOrganoidsSignal TransductionDextran SulfateInterleukin-6Receptors, Interleukin-6IL-6Rinflammationinflammatory bowel diseaseintestinal epithelial cellsTregs

Identifiers

PMID40820933
PMCPMC12724081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.